Development of gene delivery liposome vector for suicide gene therapy
Development of gene delivery liposome vector for suicide gene therapy
批准号:
14572040
负责人:
MAITANI Yoshie
金额:
$1.73万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2002
资助国家:
日本
项目状态:
已结题
起止时间:
2002 至 2004
中文摘要
点击翻译按钮获取中文摘要
英文摘要
For injectable sized liposomes with high transfection efficiency of genes, liposomes complexed with plasmid DNA (lipoplexes) and liposomes-entrapping DNA(LED) were studied to optimize the formulae and preparation. For selectivity of gene expression, the thymidine kinase gene controlled by midkine promoter (pMK-tk) was used for herpes simplex virus thymidine kinase (HSV-tk) gene therapy. Liposomes composed of 3([N-(N',N'-dimethylaminoethane)-carbamoyl] cholesterol (DC-Chol), L-dioleoylphosphatidylethanolamine(DOPE) and a biosurfactant such as β-sitosterol β-D-glucoside (Sit-G) or mannosylerythrytol lipid A(MEL)(Sit-G-liposomes or MEL-liposomes, respectively) were prepared by a modified ethanol injection method. Sit-G- and MEL-liposomes produced about 300-nm sized lipoplexes. RA-LED composed of phosphatidylcholine, dioleoyl-3-trimetylammonium propane (DOTAP), DOPE, Sit-G, and retinoic acid(RA), was prepared by a modified dehydration rehydration vesicle method. By optimization of the sucrose : lipid weight ratio, 313-nm sized RA-LED with 66% entrapment efficiency could be formed. Lipoplexes of Sit-G-and MEL-liposomes and RA-LED showed higher transfection efficiency of the luciferase marker gene and thymidine kinase activity in the presence of serum in the cells. The treatment with transfection of pMK-tk by Sit-G-liposome reduced tumor growth at 4-6 days after starting transfection and injection of ganciclovir in a solid tumor model. These liposomes are promising vectors in gene-based therapy.
期刊论文(46)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
DOI:
--
发表时间:
2003
期刊:
Stp Pharma Sciences
影响因子:
--
作者:
[Kent G. Lau;S. Chopra;Y. Maitani]
通讯作者:
Kent G. Lau;S. Chopra;Y. Maitani
T.Nagamoto, Y.Hattori, K.Takayama, Y.Maitani: "Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery"Pharm.Res.. 21(4). 671-674 (2004)
T.Nagamoto、Y.Hattori、K.Takayama、Y.Maitani:“新型壳聚糖颗粒和壳聚糖包被的乳液通过鼻内疫苗递送诱导免疫反应”Pharm.Res.21(4)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
リポソームからなる遺伝子導入用キャリア
由脂质体组成的基因转移载体
DOI:
--
发表时间:
2004
期刊:
影响因子:
--
作者:
[]
通讯作者:
X.Qi, M.H.Liu, H.Y.Liu, Y.Maitani, T.Nagai: "Topical econazole delivery using liposomal gel"S.T.P.Pharm.Sci.. 13(4). 241-245 (2003)
X.Qi、M.H.Liu、H.Y.Liu、Y.Maitani、T.Nagai:“使用脂质体凝胶进行局部益康唑递送”S.T.P.Pharm.Sci.. 13(4)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
米谷芳枝: "遺伝子導入用リポソームキットとその調製法"Pharm. Tech. Japan. 16(8). 1221-1229 (2000)
Yoshie Yonetani:“用于基因转移的脂质体试剂盒及其制备方法”,Pharm.16(8)(2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 26 条
Development of targeting liposomal drugs using functional coating a folate-polymer conjugate
-
批准号:23590054
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.24万
-
财政年份:2011
-
负责人:MAITANI Yoshie
-
依托单位:
Development of oligoarginine-conjugated lipid vector for gene delivery
-
批准号:19590046
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.75万
-
财政年份:2007
-
负责人:MAITANI Yoshie
-
依托单位:
Development of novel gene delivery vector using oligo-arginine lipids
-
批准号:17590043
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.05万
-
财政年份:2005
-
负责人:MAITANI Yoshie
-
依托单位:
Evaluation of nasal absorption enhancer using rheological characteristic of nasal mucus
-
批准号:08672488
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$0.9万
-
财政年份:1996
-
负责人:MAITANI Yoshie
-
依托单位:
国内基金
海外基金
Microbubble-ZPDGFRβ/PFD/liposome通过靶向肝星状细胞改善肿瘤微环境抑制肝细胞癌复发转移的作用及机制研究
-
批准号:82272000
-
项目类别:面上项目
-
资助金额:52万元
-
批准年份:2022
-
负责人:杨秀华
-
依托单位:
基于Gd-HPDO3A@Liposome-Ga-68的PET/MR用于肝肿瘤增强显像及酸碱微环境检测
-
批准号:81701761
-
项目类别:青年科学基金项目
-
资助金额:20.0万元
-
批准年份:2017
-
负责人:李潇
-
依托单位: